Artificial Neural Networks for Predicting Patient Response to Immunotherapy in Cancer Treatment

Abstract

Immunotherapy is a revolutionary cancer treatment that employs the immune system to find and kill cancer cells. Immunotherapy has great potential but isn't always effective. Traditional procedures cannot explain patient responses. They required prediction models to choose and administer the appropriate immunotherapy for each patient. ANNs and other prediction algorithms can describe complex, nonlinear relationships in large biological datasets. They precisely forecast cancer immunotherapy success. 

This study uses patient-specific biomarkers and artificial neural networks to predict cancer treatment responses. ANNs are popular in cancer research because they handle high-dimensional datasets better than statistics. Immunotherapy patterns include complex genetic, epigenetic, and environmental links and diverse immune responses. Researchers have shown that gene expression, immune cell composition, and tumour microenvironment factors may predict therapeutic effectiveness. These indicators and their interactions are confusing. Forecasting models use complicated computations and ANNs. 

Most powerful is ANNs' rule-free data learning. Helps identify hidden biomarker-treatment outcomes connections. This study examines feedforward, CNN, and RNN immunotherapy. Using genetic, transcriptomic, proteomic, and immunological data, the research will assess these models' treatment efficacy predictions. 

Inconsistent data, a complex tumour microenvironment, and poor ANN models make cancer immunotherapy prediction using ANNs difficult. While "black-box" ANNs may predict properly, their clinical relevance is limited. Discussing explainable AI (XAI) and model attention techniques may help. These tools help doctors understand and trust ANN biology projections. Makes treatment decisions better. 

The study analyses if ANNs enhance personalised treatment. Neural networks can tailor treatment to each patient for optimal outcomes and minimal adverse effects. ANN models can optimise treatment using patient-specific genetics and immune system characteristics. This personalised cancer therapy is not "one-size-fits-all". Doctors may predict immunotherapy responses and adjust treatment. 

We will demonstrate how ANNs can predict immune checkpoint inhibitor and cancer vaccine immunotherapy responses using multiple case studies and current data. We will test these models in clinical settings and explore the merits and limitations of ANN-based systems in clinical practice. Precision medicine and IoMT using ANN models may enhance treatment outcomes and predictions. 

Moral and legal problems surrounding ANN medical choices will conclude the session. Healthcare AI models must be exact and unambiguous to gain physicians', patients', and regulators' trust. This project concludes with ANN algorithm improvements, patient data integration, and therapeutically applicable real-time prediction models. 

Artificial neural networks improve cancer precision by predicting immunotherapy. ANNs may help doctors predict and modify immunotherapy regimens based on patient biomarkers, making cancer therapies more personalised, effective, and safe. additional research is needed to simplify and adapt these models to additional patients.